Pfizer Medicare Part D Formulary Placement: Bundled Up, Or Out In The Cold?
Executive Summary
Pfizer appears to have taken an all-or-nothing approach to negotiating formulary positioning for its products in Medicare Part D prescription drug plans, according to an analysis by "The Pink Sheet" of plan formularies
You may also be interested in...
Part D 2007 Negotiations: Will Rebate Emphasis Change To Pricing Demands?
The major Part D plan sponsors may have favored receiving drug rebates over drug price discounts in negotiations with pharmaceutical manufacturers for the 2006 benefit year, based on a recently released 1analysis by the Kaiser Family Foundation
Part D 2007 Negotiations: Will Rebate Emphasis Change To Pricing Demands?
The major Part D plan sponsors may have favored receiving drug rebates over drug price discounts in negotiations with pharmaceutical manufacturers for the 2006 benefit year, based on a recently released 1analysis by the Kaiser Family Foundation
Pfizer Medicare Part D Negotiations Not Focusing On Dual-Eligible Plans
Pfizer is not prioritizing preferred tier positioning in negotiations with Medicare Part D drug plans expected to enroll large numbers of dual-eligibles due to the limited difference in brand tier copays for such beneficiaries